UA27776C2 - Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців - Google Patents

Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців

Info

Publication number
UA27776C2
UA27776C2 UA93004096A UA93004096A UA27776C2 UA 27776 C2 UA27776 C2 UA 27776C2 UA 93004096 A UA93004096 A UA 93004096A UA 93004096 A UA93004096 A UA 93004096A UA 27776 C2 UA27776 C2 UA 27776C2
Authority
UA
Ukraine
Prior art keywords
substance
mammals
receptor antagonists
saults
pharmaceutically acceptable
Prior art date
Application number
UA93004096A
Other languages
English (en)
Russian (ru)
Inventor
Фумітака Іто
Фумитака Ито
Хіросі Кондо
Хироси Кондо
Каору Сімада
Каору СИМАДА
Масамі Накане
Масами Накане
Джон Адамс Лоі
Джон Адамс Лои
Террі Джей РОУЗЕН
Терри Джей Роузен
Original Assignee
Пфайзер Інк.
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA27776(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Інк., Пфайзер Инк. filed Critical Пфайзер Інк.
Publication of UA27776C2 publication Critical patent/UA27776C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Винахід належить до нових похідних хінуклідину, фармацевтичних композицій, що містять такі сполуки, і до застосування таких сполук для лікування й попередження запальних розладів і розладів центральної нервової системи. Фармацевтично активні сполуки даного винаходу є антагоністами рецепторної речовини P. Цей винахід належить також до нових проміжних сполук, що використовуються для синтезу таких антагоністів речовини Р.
UA93004096A 1991-05-31 1992-04-28 Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців UA27776C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (en) 1991-05-31 1992-04-28 bibNUCLIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
UA27776C2 true UA27776C2 (uk) 2000-10-16

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
UA93004096A UA27776C2 (uk) 1991-05-31 1992-04-28 Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців

Country Status (41)

Country Link
US (3) US5807867A (uk)
EP (1) EP0587723B1 (uk)
JP (2) JPH0733386B2 (uk)
KR (1) KR100214905B1 (uk)
CN (1) CN1048492C (uk)
AP (1) AP299A (uk)
AT (1) ATE135006T1 (uk)
AU (1) AU657552B2 (uk)
BG (1) BG61694B1 (uk)
BR (1) BR9206073A (uk)
CA (1) CA2102179C (uk)
CZ (1) CZ281403B6 (uk)
DE (4) DE122006000066I2 (uk)
DK (1) DK0587723T3 (uk)
EG (1) EG19944A (uk)
ES (1) ES2084361T3 (uk)
FI (1) FI114475B (uk)
GR (1) GR3019687T3 (uk)
GT (1) GT199200028A (uk)
HU (1) HU217548B (uk)
IE (1) IE72473B1 (uk)
IL (1) IL102008A (uk)
IS (1) IS1611B (uk)
LU (1) LU91293I2 (uk)
MA (1) MA22539A1 (uk)
MX (1) MX9202554A (uk)
NL (1) NL300250I2 (uk)
NO (2) NO302701B1 (uk)
NZ (2) NZ242956A (uk)
OA (1) OA09867A (uk)
PL (1) PL171379B1 (uk)
PT (1) PT100546B (uk)
RO (1) RO110499B1 (uk)
RU (1) RU2103269C1 (uk)
SK (1) SK390692A3 (uk)
TW (1) TW204349B (uk)
UA (1) UA27776C2 (uk)
UY (1) UY23422A1 (uk)
WO (1) WO1992021677A1 (uk)
YU (1) YU48995B (uk)
ZA (1) ZA923942B (uk)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
DE69213451T2 (de) * 1991-06-20 1997-01-09 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
CA2141048C (en) * 1992-08-19 2003-03-18 Harry R. Howard Substituted benzylamino nitrogen containing non-aromatic heterocycles
EP0668863B1 (en) * 1992-11-12 1997-01-08 Pfizer Inc. Quinuclidine derivative as substance p antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
AU751114B2 (en) * 1998-03-19 2002-08-08 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use as tachykinin receptor antagonists
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
CZ200434A3 (cs) * 2001-07-20 2005-02-16 Pfizer Products Inc. Léčivo pro léčení abnormálního úzkosného chování u domácích zvířat a způsob screeningu zkoušené sloučeniny za účelem stanovení anxiolytické účinnosti u psů
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005045395A2 (en) * 2003-10-27 2005-05-19 Meyer Donald W Method of detecting bovine spongiform encephalopathy
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US20070155782A1 (en) * 2004-01-30 2007-07-05 Hickman Mary A Nk-1 receptor antagonists anesthesia recovery
PL1713504T3 (pl) * 2004-01-30 2017-12-29 Zoetis Services Lcc Przeciwdrobnoustrojowe środki konserwujące w celu uzyskania wielodawkowego preparatu stosując beta-cyklodekstryny dla ciekłych postaci dawkowania
ATE380811T1 (de) 2004-02-02 2007-12-15 Pfizer Prod Inc Verfahren zur herstellung von 1-(2s,3s)-2- benzhydril-n-(5-tert.-butyl-2- methoxybenzyl)chinuklidin-3-amin
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (uk) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазини, бензотіазини і споріднені сполуки, що мають інгібуючу nos активність
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (uk) 2011-04-21 2015-06-12 Piramal Entpr Ltd
NO2729147T3 (uk) 2011-07-04 2018-02-03
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3609495A4 (en) 2017-04-10 2020-12-02 Chase Therapeutics Corporation NK1 ANTAGONIST COMBINATION AND METHOD OF TREATMENT OF SYNUCLEINOPATHIA
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
AU2018290889A1 (en) 2017-06-30 2020-02-13 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DK0532527T3 (da) * 1990-06-01 1995-01-02 Pfizer 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ES2147889T3 (es) * 1996-01-19 2000-10-01 Lonza Ag Metodo para preparar 3-hidroxiquinuclidinol opticamente activo.
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
CA2102179C (en) 1998-10-27
NL300250I2 (nl) 2007-03-01
MA22539A1 (fr) 1992-12-31
US5807867A (en) 1998-09-15
CN1067428A (zh) 1992-12-30
JPH06504292A (ja) 1994-05-19
SK278788B6 (sk) 1998-02-04
CN1048492C (zh) 2000-01-19
BR9206073A (pt) 1994-12-06
MX9202554A (es) 1992-11-01
AU1990192A (en) 1993-01-08
NO302701B1 (no) 1998-04-14
CA2102179A1 (en) 1992-12-01
ZA923942B (en) 1993-11-29
NO2007003I1 (no) 2007-03-26
AP9200384A0 (en) 1992-07-31
FI114475B (fi) 2004-10-29
JP2645225B2 (ja) 1997-08-25
NL300250I1 (nl) 2007-02-01
NO934312D0 (no) 1993-11-29
GT199200028A (es) 1993-11-20
HUT70151A (en) 1995-09-28
PL171379B1 (en) 1997-04-30
US5939433A (en) 1999-08-17
PT100546A (pt) 1993-08-31
NZ242956A (en) 1995-06-27
PT100546B (pt) 1999-12-31
TW204349B (uk) 1993-04-21
EG19944A (en) 1997-02-27
BG61694B1 (bg) 1998-03-31
IL102008A (en) 1995-12-08
FI935297A (fi) 1993-11-29
NZ270673A (en) 1997-07-27
CZ390692A3 (en) 1994-02-16
DE122006000066I1 (de) 2007-03-22
ES2084361T3 (es) 1996-05-01
BG98248A (bg) 1994-07-29
ATE135006T1 (de) 1996-03-15
HU217548B (hu) 2000-02-28
NO934312L (no) 1993-11-29
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
NO2007003I2 (no) 2011-04-18
WO1992021677A1 (en) 1992-12-10
FI935297A0 (fi) 1993-11-29
IS3871A (is) 1992-12-02
RU2103269C1 (ru) 1998-01-27
IE921729A1 (en) 1992-12-02
AU657552B2 (en) 1995-03-16
EP0587723A1 (en) 1994-03-23
KR100214905B1 (ko) 1999-08-02
AP299A (en) 1994-01-14
IL102008A0 (en) 1992-12-30
IE72473B1 (en) 1997-04-23
HU9303393D0 (en) 1994-03-28
DE9290063U1 (de) 1994-02-24
SK390692A3 (en) 1998-02-04
IS1611B (is) 1996-10-18
DE69208877D1 (de) 1996-04-11
GR3019687T3 (en) 1996-07-31
RO110499B1 (ro) 1996-01-30
CZ281403B6 (cs) 1996-09-11
DE122006000066I2 (de) 2007-12-06
JPH07285965A (ja) 1995-10-31
YU56492A (sh) 1995-03-27
UY23422A1 (es) 1992-11-12
JPH0733386B2 (ja) 1995-04-12
YU48995B (sh) 2003-04-30
DE69208877T2 (de) 1996-07-25
EP0587723B1 (en) 1996-03-06
DK0587723T3 (da) 1996-04-01
US6222038B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
MY132229A (en) Indole derivatives as 5-ht receptor antagonist
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
IL133988A0 (en) Indole derivatives as mcp-1 receptor antagonists
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
CA2109415A1 (en) Substituted 3-Aminoquinuclidines
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
CA2134964A1 (en) Bridged Aza-Bicyclic Derivatives as Substance P Antagonists
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
UA41311C2 (uk) КОНДЕНСОВАНІ ІНДОЛЬНІ ПОХІДНІ ЯК АНТАГОНІСТИ 5НТ<sub>4</sub> РЕЦЕПТОРА, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
BG101715A (en) Tetracyclic spiro compounds, process for their preparation and their use as 5ht 1 d receptor antagonists
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
WO1996023769A3 (en) Heterocyclic compounds possessing 5ht2c receptor antagonist activity
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
DE69330754T2 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
ES2105664T3 (es) Procedimiento para la preparacion y resolucion de 2-fenil-3-aminopiperidina.
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
IT1276167B1 (it) Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni
TW231970B (uk)
ITTO930661A1 (it) Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
ATE288756T1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden